{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:44:56Z","timestamp":1772768696901,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.humpath.2025.106022","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T07:46:46Z","timestamp":1765957606000},"page":"106022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A practical approach for assessing\u00a0high-grade diffuse gliomas and meningiomas"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1778-8880","authenticated-orcid":false,"given":"Yi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Rudolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge A.","family":"Trejo-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Camelo-Piragua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-7441","authenticated-orcid":false,"given":"Aditya","family":"Raghunathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2025.106022_bib1","series-title":"WHO classification of tumours editorial board. Central nervous system tumours. 5th ed. Lyon:","year":"2021"},{"key":"10.1016\/j.humpath.2025.106022_bib2","article-title":"cIMPACT-NOW update 9: recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics","volume":"7","author":"Aldape","year":"2025","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.humpath.2025.106022_bib3","article-title":"cIMPACT-NOW update 11: proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors","author":"Wesseling","year":"2025","journal-title":"Brain Pathol"},{"key":"10.1016\/j.humpath.2025.106022_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/bpa.12732","article-title":"cIMPACT-NOW: a practical summary of diagnostic points from round 1 updates","volume":"29","author":"Louis","year":"2019","journal-title":"Brain Pathol"},{"key":"10.1016\/j.humpath.2025.106022_bib5","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.humpath.2025.106022_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40478-019-0731-5","article-title":"H3F3A-G34R mutant high grade neuroepithelial neoplasms with glial and dysplastic ganglion cell components","volume":"7","author":"Andreiuolo","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.humpath.2025.106022_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0165-5728(85)80063-1","article-title":"Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes","volume":"8","author":"Eng","year":"1985","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.humpath.2025.106022_bib8","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/S0002-9440(10)63730-3","article-title":"Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas","volume":"164","author":"Yokoo","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2025.106022_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2990.2004.00612.x","article-title":"Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification","volume":"31","author":"Mokhtari","year":"2005","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.humpath.2025.106022_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.prp.2017.12.009","article-title":"Immunohistochemical comparative analysis of GFAP, MAP - 2, NOGO - a, OLIG - 2 and WT - 1 expression in WHO 2016 classified neuroepithelial tumours and their prognostic value","volume":"214","author":"Schwab","year":"2018","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.humpath.2025.106022_bib11","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/neuonc\/nou097","article-title":"Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma","volume":"16","author":"Chen","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.humpath.2025.106022_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40478-017-0449-1","article-title":"Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours","volume":"5","author":"Haque","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.humpath.2025.106022_bib13","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2020.11.012","article-title":"Histone H3.3G34-Mutant interneuron progenitors Co-opt PDGFRA for gliomagenesis","volume":"183","author":"Chen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2025.106022_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jnen\/nlac102","article-title":"H3 G34 mutation assessment for diffuse gliomas in adults: when would testing be most diagnostically useful?","volume":"82","author":"Trejo-Lopez","year":"2022","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.humpath.2025.106022_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/jnen\/nlad089","article-title":"Diffuse hemispheric glioma with H3-3B G34R mutation: expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant","volume":"83","author":"Nazem","year":"2023","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.humpath.2025.106022_bib16","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.humpath.2025.106022_bib17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3171\/2015.9.JNS15754","article-title":"The simpson grading revisited: aggressive surgery and its place in modern meningioma management","volume":"125","author":"Gousias","year":"2016","journal-title":"J Neurosurg"},{"key":"10.1016\/j.humpath.2025.106022_bib18","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1038\/s41591-024-03167-4","article-title":"Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2025.106022_bib19","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1002\/cncr.29639","article-title":"Extent of resection and overall survival for patients with atypical and malignant meningioma","volume":"121","author":"Aizer","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2025.106022_bib20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/02688697.2019.1661965","article-title":"The outcome of patients with surgically treated meningioma in England: 1999-2013. A cancer registry data analysis","volume":"33","author":"Brodbelt","year":"2019","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.humpath.2025.106022_bib21","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.humpath.2025.106022_bib22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5414\/NP300750","article-title":"Brain invasion assessability in meningiomas is related to meningioma size and grade, and can be improved by extensive sampling of the surgically removed meningioma specimen","volume":"33","author":"Pizem","year":"2014","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.humpath.2025.106022_bib23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00401-022-02455-y","article-title":"Intratumor and informatic heterogeneity influence meningioma molecular classification","volume":"144","author":"Vasudevan","year":"2022","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.humpath.2025.106022_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/neuonc\/noae170","article-title":"cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas","volume":"27","author":"Sahm","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.humpath.2025.106022_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bpa.12174","article-title":"Mitotic index is an independent predictor of recurrence-free survival in meningioma","volume":"25","author":"Olar","year":"2015","journal-title":"Brain Pathol"},{"key":"10.1016\/j.humpath.2025.106022_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2990.2004.00621.x","article-title":"The accuracy of meningioma grading: a 10-year retrospective audit","volume":"31","author":"Willis","year":"2005","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.humpath.2025.106022_bib27","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/his.14543","article-title":"Visual assessment of mitotic figures in breast cancer: a comparative study between light microscopy and whole slide images","volume":"79","author":"Lashen","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2025.106022_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13000-019-0839-8","article-title":"Validation of mitotic cell quantification via microscopy and multiple whole-slide scanners","volume":"14","author":"Tabata","year":"2019","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.humpath.2025.106022_bib29","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/00000478-199712000-00008","article-title":"Meningioma grading: an analysis of histologic parameters","volume":"21","author":"Perry","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2025.106022_bib30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bpa.12524","article-title":"Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis","volume":"28","author":"Tauziede-Espariat","year":"2018","journal-title":"Brain Pathol"},{"key":"10.1016\/j.humpath.2025.106022_bib31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/jamaoncol.2025.0329","article-title":"Chromosome 1p loss and 1q gain for grading of meningioma","volume":"11","author":"Landry","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2025.106022_bib32","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/neuonc\/noab213","article-title":"A molecularly integrated grade for meningioma","volume":"24","author":"Driver","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.humpath.2025.106022_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13132","article-title":"Clinical implementation of integrated molecular-morphologic risk prediction for meningioma","volume":"33","author":"Hielscher","year":"2023","journal-title":"Brain Pathol"},{"key":"10.1016\/j.humpath.2025.106022_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00401-024-02777-z","article-title":"Loss over 5% of chromosome 1p is a clinically relevant and applicable cut-off for increased risk of recurrence in meningioma","volume":"148","author":"Maas","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.humpath.2025.106022_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnen\/nlab127","article-title":"Correlation of MTAP immunohistochemistry with CDKN2A status assessed by fluorescence in situ hybridization and clinicopathological features in CNS WHO grade 2 and 3 meningiomas: a single center cohort study","volume":"81","author":"Sasaki","year":"2022","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.humpath.2025.106022_bib36","article-title":"Molecular prognostication in grade 3 meningiomas and p16\/MTAP immunohistochemistry for predicting CDKN2A\/B status","volume":"6","author":"Tosefsky","year":"2024","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.humpath.2025.106022_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2025.106022_bib38","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S1470-2045(25)00422-X","article-title":"The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis","volume":"26","author":"Groff","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2025.106022_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/nan.70018","article-title":"Testing meningiomas with methylation arrays: insights and recommendations from a large single-centre study","volume":"51","author":"Ruiz","year":"2025","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.humpath.2025.106022_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00401-020-02247-2","article-title":"Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1","volume":"141","author":"Sievers","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.humpath.2025.106022_bib41","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.21.00784","article-title":"Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2025.106022_bib42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ajhg.2012.07.015","article-title":"Loss of SUFU function in familial multiple meningioma","volume":"91","author":"Aavikko","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.humpath.2025.106022_bib43","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.jocn.2012.05.011","article-title":"Radiation-induced meningiomas after high-dose cranial irradiation","volume":"19","author":"Godlewski","year":"2012","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.humpath.2025.106022_bib44","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/neuros\/nyy121","article-title":"Familial syndromes involving meningiomas provide mechanistic insight into sporadic disease","volume":"83","author":"Kerr","year":"2018","journal-title":"Neurosurgery"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725003090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725003090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:30:58Z","timestamp":1772724658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817725003090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"alternative-id":["S0046817725003090"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2025.106022","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A practical approach for assessing\u00a0high-grade diffuse gliomas and meningiomas","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2025.106022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106022"}}